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BACKGROUND 
 
 
Multiple myeloma is a differentiated clonal B-cell tumor, consisting in the 
early stages of the disease of slowly proliferating malignant plasma cells 
(myeloma cells). It is the second most common hematologic malignancy after 
non-Hodgkin’s lymphoma.  Normal plasma cells are very hardy cells and usually 
the only type of cell to survive the effects of myelosuppressive chemotherapy and 
radiation. The plasma cells have abnormal cytogenetics even at the stage of 
monoclonal gammopathy of undetermined significance, as evidenced by 
fluorescence in-situ hybridization (FISH) or cIg/DNA content (1-3).  Before it 
transforms to an aggressive disease, which is typically associated with 
extramedullary disease, immature morphology of the myeloma cells, rapid 
proliferation and increase in LDH, the disease is entirely bone marrow stroma-
dependent and, therefore, contained within the active hematopoietic bone marrow, 
although breakout lesions from the bone can be seen. The myeloma cell displays 
on its membrane a multitude of receptors, the ligands of which are present in the 
micro-environment. Such receptors are the IL-6 receptor, the IL-15 receptor, the 
IGF (insulin-like growth factor) receptor, CD38 and Notch (4-7). Binding of these 
receptors by their ligands results in the activation of four major pathways : STAT-
3, RAS, Akt and NF-kB, which promote growth and survival of the myeloma 
cells and also result in the secretion by the plasma cells of angiogenic factors (8-
11) . There is a tremendous redundancy in this system so that blocking one of 
these pathways will have little effect on the survival and growth of myeloma cells. 
This is in contrast to chronic myeloid leukemia where blocking of a single 
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pathway (BCR-ABL) will have a major effect on the disease.  In addition to 
supporting growth and survival, the micro-environment also places most of 
myeloma cells in a deep G1 phase by up-regulation of p21 and p27. This is 
accomplished by binding of fibronectin and V-CAM present in the micro-
environment to VLA-4 (CD49d) expressed on the membrane of myeloma cells, as 
well as by Jagged-1 induced Notch signaling (12,13).  Cells in the G1 phase of the 
cell cycle are very poor targets for conventional dose chemotherapy.  
It is very likely that in myeloma just as many other cancers, a cancer stem 
cell population exists. It is estimated that one in 10,000 to one in 20,000 
malignant cells is a cancer stem cell. Based on the extensive somatic mutations in 
the complementarity regions of the gene coding for the heavy chain, it is very 
likely that this cancer stem cell arises from a B-cell that has had extensive 
exposure to antigen in the germinal center and therefore most likely is either a 
memory B-cell or a plasmablast (14,15). It has been proposed that the myeloma 
cancer stem cell is CD138-negative and CD19-positive, based on the observation 
that this population, whether derived from myeloma cell lines or primary 
myeloma samples has an increased clonogenic potential (16). The clonogenic 
potential of myeloma cells is increased by dendritic cells, leading to loss of 
CD138 and expression of bcl-6 (17). Hedgehog signaling, which determines the 
fate of progenitor cells, promotes the expansion of the myeloma stem cell (18). 
The small subset of myeloma cells that manifests hedgehog pathway activation is 
markedly concentrated in the tumor stem cell compartment.  If there is indeed a 
myeloma stem cell, such a cell will have many characteristics in common with a 
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hematopoietic stem cell in that it is resistant to conventional doses of 
chemotherapy, and that such doses of chemotherapy will be necessary, which can 
at least eradicate hematopoietic stem cells, and therefore such therapy will require 
stem cell support. The agents most toxic to hematopoietic stem cells are alkylators 
such as melphalan, busulfan and BCNU, agents found to be very effective in 
myeloma, while other alkylators such as cyclophosphamide and platinum 
compounds, which spare hematopoietic stem cells, are much less effective in 
myeloma even at higher doses. The difficulty in myeloma is not to eradicate the 
more differentiated myeloma compartment, which comprises more than 99.9% of 
the tumor mass, but to also kill the myeloma stem cells. Consequently, achieving 
a hematologic remission, as currently defined, will have a poor correlation with 
long-term outcome and should not be used as an early substitute for survival 
estimates. 
 
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 
MULTIPLE MYELOMA 
 
AUTOLOGOUS TRANSPLANTATION FOR RECENTLY DIAGNOSED 
MYELOMA PATIENTS 
 
It has been more than 25 years since the late Tim McElwain and 
colleagues introduced high-dose melphalan for the treatment of multiple 
myeloma. Administration of melphalan 100-140 mg/m
2
 without stem cell support 
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induced biochemical and bone marrow remissions in three (all previously 
untreated) of the nine myeloma patients, which was much higher than the 3-5% 
complete response typically seen with conventional therapy (19). The efficacy of 
high dose melphalan in myeloma was subsequently confirmed in larger studies 
(20,21). However, high-dose melphalan induced prolonged aplasia of 5 to 8 
weeks and was therefore associated with high morbidity and mortality rates in a 
disease with a median age of 67 years (19,22). This led other investigators to the 
concept of stem cell rescue, which allowed further dose escalation of melphalan 
to 200 mg/m
2
. Stem cell support was initially provided with autologous bone 
marrow, which could contain up to 30% plasma cells (23), and subsequently with 
peripheral blood stem cells, containing more CD34
+
 cells/kg and therefore 
resulting in more prompt bone marrow recovery and less morbidity and mortality. 
Indeed, with a dose of 5 x 10
6
 CD34
+
 cells/kg or more, the median time of severe 
neutropenia and thrombocytopenia is not much longer than one week (24). This 
made application of autologous hematopoietic stem cell transplantation (HSCT) 
feasible in patients 60 to 75 years old, who were in otherwise good clinical 
condition, and it reduced procedure-related mortality to 2-5% (25), which is not 
higher than that seen with 6 months of conventional chemotherapy and/ or the 
novel agents, such as bortezomib, thalidomide and lenalidomide (26-29). In an 
attempt to minimize toxicity and to maximize myeloma cell kill, the concept of 
tandem autologous transplantation was introduced by Barlogie and colleagues in 
Total Therapy I (30). The underlying hypothesis was that rather than giving a 
single very intensive preparative regimen prior to stem cell rescue, providing 
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effective, but less toxic high-dose chemotherapy twice would be better tolerated 
in older patients and equally effective. Total therapy I was designed to include all 
active agents available at that time for the treatment of myeloma to increase the 
complete remission rate as a first important step to improve overall survival. A 
total of 231 patients were enrolled from 1990 to 1994. With a median follow up of 
12 years, 62 patients are still alive and 31 have not progressed. Patients still alive 
more likely had normal cytogenetics, a normal C-reactive protein (CRP), 
hemoglobin and lactate dehydrogenase (LDH) level, and had completed two 
transplants within a 12-month period. The 10-year event-free and overall 
survivals were 15% and 33%, respectively.  The superiority of Total Therapy I 
over conventional treatment was established by using historical controls, matched 
for all-important available prognostic markers and who were treated on Southwest 
Oncology trials during the same period (31). Autotransplantation induced a higher 
response rate (85% vs. 52%; p < 0.001) and significantly extended event-free (49 
vs. 22 months; p = 0.001) and overall survival (62+ vs. 48 months; p = 0.01).  The 
superiority of autologous HSCT over conventional therapy was subsequently 
confirmed in prospective randomized trials. The IFM-90 study by the Intergroupe 
Francais Du Myelome (IFM) included 200 patients under the age of 65. Stem cell 
rescue was performed with bone marrow. Data were analyzed on intent to treat 
basis (32). More than one quarter of patients randomized to the transplant arm 
never received a transplant. Nevertheless, response rates (81% vs. 57%), complete 
remission rates (22% vs. 5%), and 5 year event-free (28% vs. 10%) and overall 
survival (52% vs. 12%) were significantly better in the transplant arm. This study 
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was criticized because of the small number of patients and the poor response rate 
in the control arm. In another randomized study performed in the United 
Kingdom, the Medical Research Council Myeloma VII Trial enrolled 407 
previously untreated myeloma patients younger than 65; 401 could be evaluated. 
Also in this study with a median follow up of surviving patients of 42 months, the 
complete response rate (44% vs. 8%; p <0.001), progression-free (28 vs. 20 
months; p <0.001) and overall survival (54 vs. 42 months; p = 0.04) were superior 
in the transplant arm (33). There was a trend toward a greater survival benefit of 
HSCT in patients with poor prognosis, defined as a high β2 microglobulin level of 
greater than 8 mg/L. On the other hand, three studies using either high-dose total 
body irradiation (TBI) or oral busulfan, failed to show a benefit for the transplant 
arm when compared to standard chemotherapy (34-36). In one of these studies 
(35) patients failing to respond to induction treatment were excluded from 
randomization, although it is especially in this group of patients that autologous 
HSCT shows the most benefit compared to conventional chemotherapy (see 
below). Excellent outcomes were also reported by the Royal Marsden Hospital 
group. A total of 451 myeloma patients, 51% previously untreated, received a 
single autotransplant between 1985 and 2001 (37). The treatment-related 
mortality was 6%, which is somewhat higher than in most other studies. Fifty-
nine percent of the patients achieved a complete or near-complete remission.  The 
10-year progression-free and overall survivals were 16.5% and 31.4%, 
respectively. Better overall survival was seen in patients with low β2-
microglobulin, age less than 60 years and normal albumin levels.  In its evidence-
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based review, the American Society for Blood and Marrow Transplantation 
concluded that autologous HSCT is the preferred treatment modality for myeloma 
and that its application is recommended as de novo rather than as salvage therapy 
(38). Yet, less than half of the patients aged 65 or less with myeloma actually 
proceeds to transplantation (39). Between October 1998 and February 2004, 668 
newly diagnosed myeloma patients were randomized upfront to intensive therapy 
including tandem autologous transplants with or without thalidomide during the 
whole treatment. With a median of 42 months of follow-up for surviving patients, 
the complete remission rate (62% vs. 43%; p < 0.001) and the 5-year event-free 
survival (56% vs. 44%; p = 0.01) were superior in the thalidomide arm. However, 
the 5-year overall survival was similar, approximately 65% in both arms (p = 0.9). 
Median survival after relapse was significantly shorter in the thalidomide arm (1.1 
vs. 2.7 years; p = 0.001). Toxicity was also higher in the thalidomide arm, 
especially deep vein thrombosis and peripheral neuropathy (40). When comparing 
the non-thalidomide arm of Total Therapy 2 (more intensive induction, 
consolidation and maintenance therapy) to Total therapy 1, the complete 
remission rates were similar (43% vs. 41%). However, the 5-year event-free 
survival was better on Total Therapy 2 (43% vs. 28%; p < 0.001) with also a trend 
for better overall survival (62% vs. 57%; p = 0.11). Superior event-free and 
overall survivals were seen in the two-thirds of patients with normal metaphase 
cytogenetics (40).   
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THE PREPARATIVE REGIMEN FOR AUTOLOGOUS HEMATOPOIETIC 
STEM CELL TRANSPLANTATION 
 
Most preparative regimens are based on either melphalan alone or a 
combination of melphalan and TBI. Other alkylating agents such as busulfan, 
carmustine, thiotepa and cyclophosphamide have been used less often.  The IFM 
study 9502, which included 282 newly diagnosed and evaluable myeloma patients 
under the age of 65, compared in a prospective randomized trial, melphalan 140 
mg/m
2
 with 8 Gy of TBI to melphalan 200 mg/m
2
 (41). Patients randomized to 
the melphalan arm only, showed significantly faster recovery of neutrophils and 
platelets, required less transfusions and the median duration of hospitalization was 
significantly shorter. There was a trend towards a better complete and very good 
partial remission rate in the melphalan only arm (55% vs. 43 %; p = 0.06). The 
median event-free survival was identical, but the 45-month overall survival was 
superior in the melphalan only arm (65.8% vs. 45.5%; p = 0.05), probably due to 
more effective salvage treatment in the melphalan only patients. Two additional 
non-randomized studies confirm the superiority of melphalan 200 mg/m
2
 over 
TBI-containing preparative regimens. In the University of Arkansas experience, 
TBI-containing regimens were associated with a higher treatment-related 
mortality and inferior event-free and overall survival, despite similar complete 
remission rates (42). These investigators speculated that a more profound and 
prolonged immunosuppression after TBI was responsible for the inferior outcome. 
The European Group for Blood and Marrow Transplantation (EBMT) analysis on 
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prognostic factors for outcome after autologous transplantation in myeloma also 
demonstrated that non-TBI preparative regimens were independently associated 
with a superior outcome (43). In a study from the M.D. Anderson Cancer Center, 
which included 186 newly diagnosed patients, a preparative regimen with 
thiotepa, busulfan and cyclophosphamide was compared to melphalan 200 mg/m
2
 
in a retrospective analysis. The response rate (66% vs. 69%), progression-free (21 
vs. 20 months) and overall survival (46 months vs. not reached) were similar in 
both groups. The authors concluded that a more intensive regimen did not 
improve outcome and that melphalan 200 mg/m
2
 should be the standard 
preparative regimen (44). Based on all these data, melphalan 200 mg/m
2
 has 
become the preferred preparative regimen. 
 
GRAFT CONTAMINATION WITH MYELOMA CELLS 
 
There is ample and convincing evidence that not only bone marrow, but 
also peripheral blood stem cells are contaminated with myeloma cells (45,46). 
Applying quantitative PCR amplification assays of patient-specific CDR3 DNA 
sequences on peripheral blood mononuclear cell samples, myeloma cells can be 
detected in virtually all myeloma patients (46,47). The re-infusion of 
contaminated peripheral blood stem cell collections may contribute to disease 
relapse as has been demonstrated for other malignancies such as acute and chronic 
myeloid leukemia, and neuroblastoma (48,49). Additionally, an inverse 
correlation has been established between plasma cell contamination of the 
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peripheral blood stem cell product and disease-free survival, although this was a 
small study which include only 33 patients (50). This may be more a reflection of 
the higher tumor burden than contribution of contaminated myeloma cells to 
relapse. Indirect evidence of the potential importance of a clean graft comes from 
an EBMT study, comparing outcomes of 25 myeloma patients, receiving bone 
marrow or peripheral blood stem cells from an identical twin to 125 case-matched 
controls who received autologous and thus contaminated transplants (51). The 
overall survival tended to be better (73 vs.  44 months; p = 0.1) and progression-
free survival was significantly better (72 vs. 25 months; p = 0.009) for the 
syngeneic transplants. The risk of relapse at 48 months was significantly lower 
(36% vs. 78%; p = 0.009).  Different ex vivo purging techniques, based on 
chemical and immunologic approaches have been applied to obtain “tumor-free” 
grafts. Delayed hematologic recovery and increased infectious complications have 
compromised the applicability of these strategies, despite their success in 
substantially reducing myeloma cell contamination of the graft. In a multi-center 
Phase III randomized trial, hematologic recovery and toxicity after autologous 
transplantation were compared between patients receiving CD34
+
 cell-selected 
grafts versus unselected grafts (52). Time to platelet recovery was slightly delayed 
in patients receiving CD34
+
 cell-selected grafts with less than 2 x 10
6
 CD34
+
 
cells/kg. There was no difference in event-free and overall survival between the 
two arms. Moreover, salvage therapy may be more difficult in patients who have 
received CD34
+
 cell-selected grafts. Because of the high cost and the lack of 
benefit of tumor cell-reduced grafts, this area of research is no longer pursued.   
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SINGLE VERSUS TANDEM AUTOLOGOUS TRANSPLANTS 
 
Despite the superiority of autologous transplantation over conventional 
chemotherapy, the 7-year event-free survival in the IFM 90 trial was only 16% 
with no plateau on the survival curve. Achievement of a very good partial 
response (VGPR; i.e. more than 90% reduction in M-protein) or better was 
associated with a significantly better overall survival. Therefore, the same French 
group tested in a prospective randomized trial (IFM 94) whether outcome could 
be improved by the application of tandem transplants (53). In that study 399 
newly diagnosed myeloma patients under the age of 60 years were randomly 
assigned to a single versus tandem transplants. Patients in the single transplant 
arm received melphalan 140 mg/m
2
 with 8 Gy of TBI, while those in the tandem 
transplant arm received a first transplant with melphalan 140 mg/m
2
, followed by 
melphalan 140 mg/m
2
 with 8 Gy of TBI for the second transplant. No difference 
was observed in the VGPR or better rate between the two arms (50% vs. 42%; p = 
0.1). However, the event-free (20% vs. 10%; p = 0.03) and overall survival at 7 
years (42% vs. 21%; p = 0.01) was superior in the tandem transplant arm. For 
patients in the single transplant arm who did not achieve at least a VGPR within 3 
months after transplant the 7-year survival was only 11% versus 43% in the 
tandem transplant arm (p < 0.001). However, patients achieving at least a VGPR 
after a single transplant did not appear to benefit significantly from a second 
transplant (p = 0.7). On multivariate analysis, β2 microglobulin, LDH and the 
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treatment arm were all independent prognostic markers associated with survival 
(all p < 0.01).  In another prospective randomized study, the Bologna 96 clinical 
study of single versus double autologous HSCT for myeloma, 321 patients were 
randomly assigned to receive either melphalan 200 mg/m
2
 alone or melphalan 200 
mg/m
2
 followed by melphalan 120 mg/m
2
 plus busulfan 12 mg/kg (54). A higher 
percentage of patients in the double transplant arm achieved at least a near 
complete remission in the tandem transplant arm (47% vs. 33%; p = 0.008) and 
these patients had a longer relapse-free (42 vs. 28 months; p < 0.001) and event-
free survival (35 vs. 23 months; p = 0.001). Benefits offered by tandem 
transplantation were particularly evident among patients failing to achieve at least 
a near complete remission after the first transplant. Transplant-related mortality 
was 3% in the single and 4% in the tandem transplant arm. The administration of 
a second transplant and the introduction of novel agents in the treatment of 
myeloma for patients relapsing in the single transplant arm resulted in a failure to 
see a benefit in overall survival for the double transplant group. Therefore, the 
available data favor tandem transplants in younger myeloma patients at least in 
those not achieving an excellent response after the first transplant. The issue of 
benefit and timing of a second autologous HSCT has been addressed in a 
retrospective analysis of the EBMT, which included approximately 7,500 patients 
(55). Since this was not a prospective randomized study, there may be major 
biases related to differences in prognostic factors and to the multiple centers who 
had contributed to the patient database. On the other hand, the large number of 
patients analyzed probably compensated for many of these biases. In this study, 
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the hazard ratio (HR) of relapse was clearly lower if a second transplant was 
performed within 12 months after the first transplant (HR compared to no second 
transplant was 0.43 for second transplants performed < 6 months after the first 
and 0.51 between 6 and 12 months). A second transplant more than 12 months 
after the first transplant still had a significantly lower relapse rate compared to no 
second transplant before relapse (HR = 0.64), but its benefit was not as 
pronounced as with a second transplant within 12 months. Moreover, the 
transplant-related mortality was clearly higher if the second transplant was 
performed more than 12 months after the first. When in this retrospective analysis 
an elective second transplant was compared to a second transplant at relapse, an 
elective second transplant clearly improved overall survival (HR for survival 1.7; 
p < 0.0001), while a second transplant at relapse did not confer any survival 
benefit over salvage treatment with non-transplant modalities (HR = 1.06; p = 
0.55).  
 
AUTOLOGOUS TRANSPLANTATION FOR PRIMARY REFRACTORY 
MYELOMA 
 
High dose therapy has consistently increased tumor cytoreduction and has 
extended event-free and overall survival in patients with primary refractory 
myeloma (<50% reduction in M-protein). Alexanian and colleagues reported on 
27 patients with primary refractory myeloma who received an autologous 
transplant and compared their outcome to 60 control patients receiving 
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conventional chemotherapy (56). The transplanted patients had a median survival 
of 83 months compared to 38 months for patients receiving standard treatments 
for primary refractory myeloma (p = 0.03). Autologous transplantation for 
primary refractory myeloma later in the disease (> 1 year), resulted in 
significantly lower response rates and shorter progression-free survival. In a study 
from the Royal Marsden Hospital, Surrey, UK, patients with primary refractory 
myeloma to induction therapy had a similar event-free survival compared to those 
with chemotherapy-sensitive patients (p = 0.2) with an early difference in 
outcome in favor of the chemotherapy-sensitive patients, mainly due to the higher 
transplant-related mortality in the primary refractory patients (57). The time to 
relapse was also identical in the two groups (p = 0.6). The authors concluded that 
myeloma patients should not be excluded from autologous HSCT based upon lack 
of response to induction chemotherapy. The Mayo Clinic reported their 
experience with outcome of stem cell transplantation in 50 patients with primary 
refractory myeloma to induction therapy and compared it to that of 101 patients 
with chemotherapy-sensitive disease (58). The one year progression-free survival 
for refractory patients was 70% compared to 83% for chemotherapy-sensitive 
patients (p = 0.65). The authors recommended early stem cell transplantation for 
patients with primary refractory myeloma.  
 
AUTOTRANSPLANTATION FOR ELDERLY PATIENTS 
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Most high dose therapy trials have only included relatively young patients 
with good organ function. However, the median age of myeloma patients is 67 
years. If a major impact of autologous HSCT on outcome is to be achieved, it will 
have to be performed also in patients over the age of 65. Age per se should not be 
a contra-indication for transplantation, but co-morbidities can be. It is obvious 
that co-morbidities increase in older patients, and therefore, more elderly 
myeloma patients may not be candidates for autologous HSCT. Several studies 
have reported contradictory findings on the impact of age on the ability to collect 
stem cells. In a retrospective analysis including 984 patients with 106 over the age 
of 70 years, increasing age correlated inversely with CD34
+
 cell yield (59). 
However, the overwhelming majority (85%) of elderly patients were able to 
collect greater than 4 x 10
6
 CD34
+
 cells/kg provided that the duration of 
preceding therapy was 12 months or less and the platelet count was 200,000/uL or 
more. With the introduction of peripheral blood stem cell transplants, shortening 
the duration of severe cytopenias, and the improved supportive care, the toxicity 
of autologous HSCT has clearly decreased. The Arkansas group has compared the 
outcome of 49 previously treated and untreated myeloma patients over the age of 
65 to that of pair mates matched for important prognostic factors (60).  No 
significant difference was seen in percentage of patients completing two 
transplants (65% vs. 76%; p = 0.3). Time to hematopoietic recovery after first and 
second transplant was comparable in both groups. Treatment-related mortality 
was 8% in the older and 2% in the younger patients. The frequency of complete 
remission was lower in older patients (20% vs. 43%; p = 0.02). Median durations 
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of event-free (p = 0.2) and overall survival (p = 0.4) were not significantly 
different. The safety of autologous HSCT in older patients was subsequently 
confirmed in other studies (61, 62). The role of autologous HSCT in older patients 
has recently been challenged by the IFM 99-06 trial comparing melphalan-
prednisone to melphalan-prednisone plus thalidomide and to twice melphalan 100 
mg/m
2
 with stem cell support (63). A total of 436 patients between the ages of 65 
and 75 were enrolled. Median follow-up was 32 months. Progression-free and 
overall survivals were significantly better for patients randomized to the 
melphalan-prednisone plus thalidomide. The authors concluded that melphalan-
prednisone plus thalidomide is effective treatment for older myeloma patients, 
probably superior to autologous HSCT. It should be noted, however, that 30% of 
patients randomized to transplantation never received a transplant and that the 
dose of melphalan was suboptimal even for older patients. In older patients in 
good general health, tandem autotransplants probably still is the preferred 
treatment, but the dose of melphalan should be reduced to 140 mg/m2 instead of 
200 mg/m2 to minimize toxicity and to maximize the chance that a second 
transplant can be administered in a timely fashion. 
 
AUTOTRANSPLANTATION IN PATIENTS WITH RENAL FAILURE 
 
Pharmacokinetic studies performed in 20 patients, including six with 
severe renal failure, five of which were on dialysis, showed that melphalan levels 
and metabolism were not different in patients with renal failure (64). However, 
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high dose melphalan was associated with more toxicity (p = 0.0005) and longer 
hospitalizations (p = 0.004) in renal failure patients. The Arkansas group reported 
data on 81 consecutive myeloma patients with renal failure (creatinine of > 2 
mg/dL or >176.8 umol/L) at the time of transplantation (65). Thirty-eight patients 
were dialysis dependent. The median age was 53 years and one quarter had 
received > 12 months of preceding therapy.  The first 60 patients received 
melphalan 200 mg/m
2
; the dose of melphalan was reduced to 140 mg/m
2
 for the 
last 21 patients. A complete remission of 26% and 38%, respectively, was 
observed after the first and second transplant. Median overall survival was 52+ 
months. Melphalan 140 mg/m
2
 was better tolerated and appeared equally effective 
as melphalan 200 mg/m
2
. It should be mentioned that only 40% received their 
planned second transplant. In another study from the same group of investigators, 
the outcome of 59 patients on dialysis at the time of first transplant was of 4 
months after autologous HSCT (66); 37 had been on dialysis for 6 months or less. 
The 5-year event-free and overall survivals were 24% and 36%, respectively. One 
quarter of patients became dialysis-independent. Shorter duration of dialysis- 
dependency and a pre-transplant creatinine clearance of greater than 10 mL/min 
predicted for a significantly higher probability of becoming dialysis-independent 
post-transplantation. These data suggest that autologous HSCT should be 
performed early in the disease course to maximize the probability of reversing 
end-stage renal failure.  Raab et al compared outcome of 17 patients with dialysis-
dependent renal failure, who received melphalan 100 mg/m
2
, to that of 17 
matched pairs without renal failure, treated with melphalan 200 mg/m
2
 (67). No 
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significant difference in hematologic toxicity, transplant-related mortality or 
disease response was observed, and event-free and overall survivals were 
comparable. However, dialysis-dependent patients required more extensive 
intravenous antibiotic administration and longer hospitalizations. Similar 
observations were made by Knudsen et al (68). They did observe a significantly 
higher transplant-related mortality (17% vs. 1%) in patients with severe renal 
failure. The dose of melphalan in renal failure patients varied between 100-200 
mg/m
2
.  These data clearly indicate that autologous HSCT in patients with renal 
failure is feasible and can reverse dialysis-dependency. However, it is more toxic 
and requires better supportive care skills. The dose of melphalan should be 
reduced to 100-140mg/m
2
 dependent on age and co-morbidities. 
 
PROGNOSTIC FACTORS WITH AUTOTRANSPLANTATION 
 
Myeloma is a highly heterogeneous disease with survival ranging from a 
few months to more than 15 years. The Durie-Salmon staging system, which is 
based on renal function and estimates of tumor burden, clearly has prognostic 
significance and has allowed better interpretation of clinical trials, but has major 
shortcomings such as assessment of lytic lesions and the lack of attention to 
proliferation characteristics (69). The International Staging System was 
introduced recently and is based on data of more than 10,000 patients (70).  It 
only uses albumin and β2-microglobulin levels, which are readily available to 
practicing oncologists. It clearly separates patients into good, intermediate and 
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high risk myeloma. Although this classification is now widely applied, it does not 
include any genetic information about the cancer cells. The importance of 
cytogenetics was first demonstrated by metaphase cytogenetics and subsequently 
by FISH. Patients with cytogenetic abnormalities on metaphase analysis have an 
inferior prognosis (71,72). Finding abnormal metaphase cytogenetics is probably 
the best surrogate marker available at this time for stroma-independent and, 
therefore, aggressive myeloma (73). The worst outcome is seen in patients with a 
hypodiploid karyotype and/or complete deletion of chromosome 13 or partial 
deletion of its long arm (74). Patients with a hyperdiploid karyotype and no 
deletion 13 have a somewhat better outcome. Chromosome 14q32 translocations, 
involving the gene coding for the immunoglobulin heavy chain are frequent in 
myeloma and probably represent an important early event in its pathogenesis, 
since these translocations are found with almost the same frequency in 
monoclonal gammopathy of undetermined significance. Multiple partners have 
been identified for the 14q32 translocations, some associated with good, others 
with poor prognosis.  The t(11;14) (q13;q32), which results in a high expression 
of cyclin D1 and present in 20% of myeloma patients, is associated with a good 
prognosis (75,76). These patients have myeloma cells with more 
lymphoplasmacytic morphology and a pseudo-diploid karyotype.  The plasma 
cells are often CD20-positive. This translocation is also common in primary 
amyloidosis (77). Although many patients with this translocation relapse, they 
remain relatively sensitive to therapy.  The t(6;14)(p21;q32), present in 5% of 
myeloma patients, results in over-expression of cyclin D3 (78). It shares the same 
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good prognosis with the t(11;14). On the other hand, the t(14;16)(q32;q23), 
present in 5% of patients and resulting in over-expression of c-MAF, 
t(14;20)(q32;q11), present in <5% and resulting in high MAF-B and the 
t(4;14)(p16;q32), present in 15% and resulting in high expression of FGFR3 in 
the majority of patients, are associated with a poor prognosis also with stem cell 
transplantation (79-82). These poor prognosis translocations can only be detected 
by FISH and not by conventional cytogenetics. They are often associated with 
deletion 13 on conventional cytogenetics. Deletion of 17p, involving the p53 gene 
is usually a mono-allelic deletion. It also has a poor prognosis and is present in 
10-33% of myeloma patients (83,84). Metaphase and FISH chromosomal analysis 
represent only a crude way to assess DNA changes and provide no clues of which 
genes are either over- or under-expressed. Gene expression profiling permits 
quantitation of RNA expression of more than 30,000 genes with many of those 
related to cancer biology such as proliferation, apoptosis, DNA repair and drug 
resistance. Applying unsupervised hierarchical clustering to highly purified 
plasma cells of newly diagnosed patients, seven subgroups of myeloma have been 
identified, based on either spiked gene expression as a consequence of a 
translocation involving 14q32, hyperdiploidy or proliferation characteristics (82). 
This biological classification also had major prognostic significance with inferior 
outcome for patients with a proliferative signature or with spikes of MMSET, c-
MAF or MAF-B, thus confirming and adding to the FISH data. To molecularly 
define high risk myeloma, 70 either highly over- or under-expressed genes were 
identified, that were linked to early myeloma–related death (85). A high 
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proportion of up-regulated genes mapped to chromosome 1q, while a high 
proportion of down-regulated genes mapped to chromosome 1p. The ratio of 
mean expression levels of up-regulated to down-regulated genes defined a group 
of high-risk patients, which constituted 13% of the entire myeloma population 
with a short event-free and overall survival. Multivariate discriminant analysis 
showed that a subset of only 17 genes predicted outcome equally well as the 70 
gene model.  On multivariate analysis of outcomes of 220 newly diagnosed 
myeloma patients entered on Total Therapy 2, including standard prognostic 
variables, metaphase cytogenetics, magnetic resonance imaging, FISH and gene 
expression profiling (GEP), the hazard ratio for overall survival was highest  for 
GEP ( 3.07; p < 0.001), followed by amplification of 1q21 (1.71; p = 0.05) (see 
below). The 3-year survival decreased progressively from 92% to 78% to 43% 
according to the presence of none (49% of patients), one (35%) or both (16%) of 
these unfavorable variables (86). One of the genes mapping to 1q21 is CKS1B. 
Over-expression of this gene is associated by itself with a poor prognosis (87). 
Over-expression of 1q21 can also be assessed by FISH. Amplification of 1q21 
(amp1q21) heralds a poor prognosis and remains an independent factor on 
multivariate analysis with an inferior event-free and overall survival (88). In the 
absence of GEP, much of the prognostic value can be assessed by combining 
metaphase cytogenetics with FISH for t(11;14) and amp1q21 with a significantly 
inferior event-free survival for patients  with cytogenetic abnormalities and 
amp1q21 but no t(11;14) (Figure 1). 
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AUTOTRANSPLANTATION FOR RELAPSED/REFRACTORY MYELOMA 
 
Although curative in only a minority of myeloma patients, the introduction 
of high-dose treatment (HDT) with autologous HSCT has led to a significantly 
longer event-free and overall survival, and to a better quality of life when 
compared to standard-dose therapy (SDT).  
The optimal time of the application of HDT in MM patients i.e. early in 
the course of the disease versus at relapse following conventional chemotherapy, 
is still controversial. Fermand et al
 
compared, in a randomized fashion, the 
outcome of the disease in two groups of relatively young (<56 years) patients; 91 
patients received HDT and autologous HSCT after a short induction treatment 
(early transplant) and 94 patients received HDT and HDT and autologous HSCT 
as rescue procedure (i.e. in case of primary resistance to conventional 
chemotherapy or at relapse; late transplant) (89). With a median follow-up of 58 
months, the overall survival was identical (64.6 vs. 64 months) in the two groups. 
In 1993, three North American cooperative groups launched a prospective 
randomized trial (S9321) comparing HDT (melphalan 140 mg/m
2
 plus total-body 
irradiation 12 Gy) with SDT using the vincristine, carmustine, melphalan, 
cyclophosphamide, and prednisone (VBMCP) regimen.  Responders on both arms 
(>75%) were randomly assigned to interferon (IFN) or no maintenance treatment.  
After induction therapy with four cycles of vincristine, adriamycin and 
dexamethasone (VAD), patients were randomly assigned to either HDT with 
melphalan plus TBI or to SDT with VBMCP for one year; all patients received 
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high-dose cyclophosphamide, and except for allogeneic HSCT candidates, 
proceeded with peripheral blood stem cell collection. Patients were stratified 
according to Durie-Salmon stage, β2-microglobulin serum level, and response to 
VAD induction.  Responding patients (>75% M-protein reduction) were 
randomly assigned to 4 years of maintenance therapy with interferon versus 
observation.  Patients treated on the VBMCP arm were offered the option of 
salvage autologous HSCT at the time of disease progression or relapse.  In the 
VBMCP arm, 87 of 157 patients with follow-up after relapse received a salvage 
autotransplant, resulting in a median survival time of 30 months (Fig. 2); this was 
slightly higher than the survival time of 23 months noted among the remaining 
patients receiving non-transplantation based salvage therapies (P=.13) (36). 
Patients with primary refractory, progressive disease, or not achieving 
50% monoclonal protein reduction with the initial standard-dose regimen respond 
differently to HDT than patients who relapse either while on conventional 
chemotherapy or after discontinuation of such treatment (see above). Vesole et al 
reported the effect of HDT on 135 patients with refractory myeloma (90). Either 
melphalan 100 mg/m
2
 (47 patients), TBI with melphalan or thiotepa (21 patients), 
melphalan 200 mg/m
2
 x 1 (25 patients) and melphalan 200 mg/m
2
 x 2 (45 
patients) were applied as preparative regimens. When compared to historic 
controls, even among patients with resistant relapse and high β2-microglobulin 
levels, more intensive treatment resulted in superior event-free and overall 
survival durations. Primary refractory patients treated with TBI experienced 
significantly longer event-free and overall survival durations (32 and 66 months, 
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respectively) than those with resistant relapse (4 and 7 months, respectively; p = 
0.007, 0.007 respectively).  Similar results were observed in melphalan 200 
mg/m
2
 recipients.  Primary refractory patients experienced longer event-free and 
overall survival durations (4 and 7 months, respectively) than those with resistant 
relapse (17 and 21 months, respectively; P=0.006, 0.01 respectively).  In a subset 
analysis reported by the University of Arkansas,
 
primary refractory status was 
also associated to superior event-free survival (23 vs. 14 months; p = 0.002) and 
overall survival (39 vs. 25 months; p = 0.08) compared to patients with resistant 
relapse (22). The effectiveness of HDT in refractory MM (relapsed and primary 
refractory) was also evident in an Intergroup trial (91). On an intent-to-treat basis 
from transplant registration, the median progression-free survival and overall 
survival duration in a group of 66 patients with refractory myeloma to alkylating 
agents, dexamethasone or VAD was 11 and 19 months, respectively. Rajkumar et 
al 
 
reported on 75 patients who received transplantation for relapsed or primary 
refractory myeloma; the OS for conventionally treated patients, relapsed myeloma 
after conventional therapy, and primary refractory individuals, differed 
significantly with median survivals of 12, 21 and 30 months, respectively (92).  
Plasma cell labeling index was significantly lower in patients with primary 
refractory disease when compared with relapsed cases, suggesting that the low 
proliferative activity of the disease in the former group might partly explain the 
resistance to conventional chemotherapy. In contrast to the experience in other B-
cell malignancies, primary refractory status does not negatively affect the anti-
myeloma effect of HDT with autologous HSCT.   
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Pineda et al recently reported on the effect of high dose melphalan-based 
autotransplant for multiple myeloma (93). A total of 1064 previously treated 
patients enrolled on different HDT protocols were examined.  Trials included, for 
previously treated patients, induction with DT-PACE (dexamethasone, 
thalidomide, cisplatin, adriamycin, cyclophosphamide, and etoposide) followed 
by intended tandem transplants either with MEL200 (melphalan 200 mg/m
2
) or 
MEL140 (melphalan 140 mg/m
2
) in case of renal insufficiency with creatinine 
greater than 3 mg/dL or advanced age greater than 70 years (94). Others received 
a MEL-DT-PACE hybrid regimen (MEL140 plus DT-PACE). In case partial 
response (PR) was not achieved after the first transplant, second transplant 
regimens used MEL140 plus either TBI or high-dose cyclophosphamide or the 
BEAM regimen (carmustine [BCNU], etoposide, arabinosyl cytosine, melphalan) 
(95).  Myeloma responses were reported according to the Blade criteria.  Median 
follow-up was 38 months (range, 0.6 -201). The Kaplan-Meier method was 
applied to estimate event-free and overall survival, and comparisons between 
different arms were made using the log-rank test.  Event-free survival (median = 
24 months) and overall survival (median = 44 months) were measured from the 
first day of melphalan administration until disease recurrence or death. Overall 
survival according to the number of favorable pre-transplant parameters for all 
enrolled patients is shown in Figure 4. 
Significant differences were observed between the 5 subgroups: outcomes 
worsened progressively as the number of good-risk features declined from 5 to 4 
to 3 to 2 to less than 2. Ten-year overall survival was 25% with the best and 2% in 
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the worst constellation of prognostic factors. As most patients eventually relapse 
after one or two cycles of HDT, it is important to consider the issue of further 
treatment intensification as salvage approach. Resistance of the malignant clone 
and subclinical toxicity to vital organs may compromise long-term survival. 
Mansi et al were the first to prove “continuing chemosensitivity” by reporting a 
response rate of 93% and a response duration of 17 months in a group of 29 
patients who, after relapsing following a single course of melphalan 140 mg/m
2
, 
were treated with re-induction therapy followed by melphalan 200 mg/m
2
 and 
autologous bone marrow transplant (96). At the University of Arkansas, the 
outcome of 196 patients who relapsed after a single or double transplant was 
evaluated (97).
   
Patients received standard-dose treatment or a further transplant. 
Multivariate analysis showed that patients who relapsed late (>1 year) after the 
previous HDT and had low β2-microglobulin levels at the time of relapse were 
the best candidates for further autotransplantation. Among
 
a total of 1358 patients 
receiving two prior autologous transplants
 
(median interval from first to second 
transplant = 4 months), 98 received a further autologous transplant at relapse. In a 
search
 
for favorable  features associated with post-third autotransplant
 
survival, 
pre-transplant 1, 2 and 3 features, especially the
 
presence of metaphase 
cytogenetic abnormalities (CA) and standard laboratory
 features such as, β2-
microglobulin, CRP, LDH, albumin, hemoglobin and creatinine
 
were examined as 
well as the time interval from second to third transplant
 
and whether a third 
transplant was applied to rescue Total Therapy 1 or 2 (newly diagnosed) or other 
patients receiving tandem transplants after more extensive prior treatment (98,40). 
Chap 14 - 29 
Remarkably, the presence of CA at any of
 
the indicated time points had no impact 
on survival after a
 
third autologous HSCT, typically with a melphalan 200mg/m
2 
preparative regimen. According
 
to multivariate analysis, the second to third 
transplant interval
 
(time-dependent covariate analysis) (HR 8.8, p=.002) and 
hypo-albuminemia
 
< 3.0g/dL (HR 3.2, p<.0001) were independently important.
 
Thus, post-third transplant survival was superior among the 41 patients
 
with a 
post-second transplant event-free survival greater than 3 years and albumin 
greater than 3.0 gm/dL prior to the third transplant (median overall survival = 21 
months; 5-year overall survival = 20%), with an intermediate outcome noted for
 
the 34 patients with one of these favorable features present
 
(median overall 
survival = 10 months; 3-yr overall survival = 20%) while the worst outcome was 
noted
 
in the 13 patients who were both hypo-albuminemic and had received
 
their 
3
rd
 transplant within 3 years of the second transplant (median overall survival =
 
3 
months, no survival beyond 12 months)
 
(99). Prolonged overall survival with 
second on-demand autologous transplant in multiple myeloma has been reported 
by Elice, et al (100).
 
 A total of 130 consecutive multiple myeloma patients were 
treated with autologous HSCT after conditioning with melphalan 200 mg/m
2
 
followed by a second autologous HSCT at relapse or disease progression. A total 
of 107 (82%) patients completed the first autologous HSCT. The best response 
obtained after autologous HSCT was complete response (CR) in 23%, very good 
partial response (VGPR) in 28%, partial response (PR) in 42%, and minimal 
response (MR) in 7%. Median overall and event-free survival were 65.4 and 27.7 
months, respectively. Myeloma relapse or progression was observed in 70 
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patients; 26 received a second autologous HSCT (with a median time of 20.4 
months from first autologous HSCT). A major response (partial remission or 
better) was obtained in 69% of these patients. Median overall and event-free 
survival rates after the second autologous HSCT were 38.1 and 14.8 months, 
respectively. Treatment-related mortality was 1.9% after the first autologous 
HSCT and no deaths occurred related to the second transplant, confirming that a 
second autologous HSCT at relapse or progression is a safe and effective strategy. 
Even in the era where new drugs such as thalidomide, lenalidomide and 
bortezomib alone or in combination have produced significant responses and may 
also have a positive effect on survival of myeloma patients, HDT remains a 
valuable option in the treatment of myeloma patients relapsing after 
transplantation, especially those with more durable responses after initial 
transplant(s). After the salvage transplant, a combination of newer drugs with 
dexamethasone can be applied to increase the response duration. 
 
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 
MULTIPLE MYELOMA 
 
 Though new insights into its biology have identified molecular 
mechanisms that have become targets of recently developed agents with potent 
anti-tumor activity, multiple myeloma remains a fatal plasma cell malignancy 
(101,102). High-dose chemotherapy with autologous HSCT, after induction with 
chemotherapy or newer agents, is regarded as the standard of care for newly 
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diagnosed myeloma patients younger than 65 years (30,32,33,53,54).
 
However, 
relapse is a continuous risk and only a few good-prognosis patients live disease-
free for longer than 10 years (33,53).
 
Constant recurrence following autologous 
HSCT is primarily due to their failure to eradicate all myeloma cells. Conversely, 
allogeneic HSCT remains the only potentially curative treatment for its well 
documented graft-versus-myeloma effects (103). Given the high transplant 
mortality and morbidity related to the high-dose myeloablative preparative 
regimens used until recently, its application has primarily been limited to younger 
relapsed/refractory patients (104-106). These limitations have lately been 
significantly reduced through reduced-intensity or non-myeloablative 
conditioning regimens (107). The introduction of less intense conditionings has 
led to at least two important clinical and biological implications: the increase of 
the eligible age for allogeneic HSCT up to 65-70 years even in medically unfit 
patients and the shift of the burden of tumor eradication from the chemotherapy of 
the conditioning to the immune attack of myeloma cells by donor T cells 
(108,109). Though the results of recent trials are promising, the subset of patients 
who may most benefit from an allograft remains to be defined. The clinical 
outcomes of myeloablative and reduce-intensity/non-myeloablative allogeneic 
HSCT, the biological concepts of graft-versus-myeloma effects and possible 
future developments are reported below.  
 
ALLOGRAFTING AFTER MYELOABLATIVE CONDITIONING REGIMENS   
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High treatment-related mortality (TRM) has restricted this approach to 
young, medically fit patients, and even here transplant-related mortality rates are 
of the order of 30-60% (104-106). The recent shift from myeloablative, high-dose 
conditionings to reduced-intensity/non-myeloablative regimens has further limited 
its clinical application. Most commonly used myeloablative conditioning 
regimens (Table 1) have included cyclophosphamide with TBI, or busulfan with 
cyclophosphamide, or melphalan and TBI (104-106, 36,110-118).  
 Even though chemotherapy-sensitive disease has almost universally been 
reported as a prerequisite for higher response rates and post-transplant overall and 
disease-free survivals, the outcome of most trials of allogeneic HSCT for multiple 
myeloma has been strongly biased by patient selection and pre-transplant 
characteristics. Comparing results reported in different studies is therefore 
extremely difficult and not very helpful to establish the curative potential of the 
procedure. Overall, clinical complete remissions (CCR) have been observed in 
20-60% of patients though variable definitions of complete remission have been 
used (104-106, 36,110-118). Widely used criteria for CCR require negative 
immunofixation of both serum and urine monoclonal paraproteins with no 
evidence of myeloma cells on bone marrow biopsy and bone marrow aspirate by 
morphology and flow cytometry (119). In most trials, approximately 50% of 
patients with chemotherapy-sensitive disease at the time of transplant have 
achieved a CCR with a median onset 3 months after transplant. Overall, despite 
these high rates of CCR, late relapses occur, and in most series, only 10-25% of 
patients remain disease-free after 10 years and possibly cured. Disease remission, 
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in this subset of patients, is frequently detected by molecular methods. Molecular 
remissions, as a prelude to tumor eradication and eventual cure, are far more 
frequent after myeloablative allogeneic HSCT as compared to autologous HSCT 
and can occur in up to 50% of patients in CCR after allografting (119). In a subset 
of patients, these remissions are prolonged, suggesting a complete eradication 
(120).  
The majority of allogeneic HSCT trials have enrolled younger patients 
usually in their fifth decade. Despite this, the reported early TRM ranges from 20 
to 50% (104-106, 36, 110-118). Causes of death are primarily regimen-related, 
graft-versus-host-disease (GvHD) and its treatment-related opportunistic 
infections. Overall, the reason of the high TRM observed in multiple myeloma 
rather than other hematological malignancies remains unknown. Possible 
explanations include myeloma effects on baseline organ functions and, 
importantly, a profound immunodeficiency predisposing to organ toxicities and 
opportunistic infections. Interestingly, the largest multi-center analysis by EBMT 
registry clearly suggested that survival improved in the late 90’ given a 
remarkable reduction in TRM through better supportive care and patient selection 
criteria (122). In this retrospective study on 690 patients undergoing 
myeloablative allogeneic HSCT, patients who received a bone marrow allograft 
between 1983-93 were compared to those transplanted between 1994-98. In this 
latter cohort, a subset of patients also received granulocyte-colony-stimulating 
factor (G-CSF) mobilized peripheral blood stem cells (PBSC). TRM at 6 and 24 
months was significantly lower in patients transplanted between 1994-1998 than 
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between 1983-1993 (21% vs. 38% and 30% vs. 46% respectively). However, the 
median age at transplant was only 44 years (range, 18-57), whereas the median 
age of myeloma patients at diagnosis is approximately 65 years. The reduced 
toxicity was associated with better clinical outcome, and median overall and 
progression-free survivals at 3 years increased from 35% to 55% and from 7 to 19 
months for patients transplanted between 1983-1993 and 1994-1998, respectively. 
No differences in outcomes were reported between patients who received marrow 
and those who received PBSC, though a slightly higher incidence of chronic 
GvHD was observed with the use of PBSC. More recently, Barlogie et al reported 
on the randomized US Intergroup Trial S9321 (36). Initially, the study design 
included myeloablative allografting for patients younger than 55 years with a 
suitable sibling donor. This arm was prematurely closed because of 53% TRM. 
However, 22% of the patients enrolled remain alive and progression-free at 7 
years. Importantly, the authors show that both overall and event-free survival 
curves remain flat with follow-up extending to 10 years, consistent with a cured 
subgroup of patients. 
The largest single-center experience so far reported is from the Seattle 
group (106,110). In total, 136 patients, all younger than 60 years (median ages, 
43-48 years), underwent myeloablative allogeneic HSCT between 1987 and 1999 
from related (84%) and unrelated donors (16%). Most patients were heavily pre-
treated, beyond first response or with chemotherapy-resistant disease, and only 
21% had chemotherapy-sensitive disease. Most patients received a combination of 
busulfan and cyclophosphamide with or without TBI. The study reported a 
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currently unacceptable day-100 TRM of 48%. An additional 15% of patients died 
of transplant-related causes at 1 year, most commonly due to GvHD and 
infections. Overall, the 5-year survival was 22% with disease-free survival of 
14%. However, in 34% of patients who achieved post-transplant CCR, overall and 
disease-free survivals at 5 years were 48% and 37%, respectively. Importantly, 
subgroup analyses showed that early TRM was lower, approximately 20%, for 
patients with responsive disease who were transplanted within one year from 
diagnosis.   
No prospective randomized trials have compared allografting after 
myeloablative conditioning regimen with autografting. A retrospective case-
matched analysis of 189 patients who underwent myeloablative allogeneic HSCT 
and 189 who were treated with autologous HSCT before 1995 and reported to the 
EBMT registry showed superior clinical outcomes with autografting (123). A 
more recent single-center retrospective comparison of autologous HSCT versus 
allogeneic HSCT from HLA-identical siblings or unrelated donors has been 
reported (124). One-hundred-fifty-eight patients younger than 55 years were 
transplanted through the Leukemia/Bone Marrow Transplantation Program of 
British Columbia between 1989 and 2002. Seventy-two patients received an 
allograft after myeloablative conditioning, 58 from a sibling donor and 14 from an 
unrelated donor, whereas 86 received an autograft. After a median follow up of 88 
months, 61 patients of the entire series were alive. Twenty-eight patients were 
alive following allogeneic HSCT after a median follow-up of 102 months and 33 
following autologous HSCT after a follow-up of 87 months. Twenty-one (75%) 
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out of the 28 patients who received an allograft remained in continuous remission. 
However, no statistically significant differences were observed in either overall or 
event-free survivals between the two groups. Interestingly, neither acute or 
chronic GvHD had an impact on overall or event-free survival. As the authors 
state, the lack of formal inclusion criteria led to inevitable selection bias. Patients 
with younger age and chemo-resistant disease were more likely to be offered 
allogeneic HSCT. Other confounding factors were different initial therapeutic 
strategies, conditioning regimens, prognostic factors, and comorbidities.  
Overall, in the light of the current available data, it is important to point 
out that the retrospective nature and the heterogeneous inclusion criteria and 
treatment strategies of most studies inevitably reflect a substantial selection bias 
that reduces the statistical power and prevents from determining the real role of 
myeloablative allogeneic HSCT in multiple myeloma. However, published reports 
almost unanimously conclude that better outcome is associated with chemo-
sensitive disease at transplant and, importantly, that allografting at an earlier 
disease phase is associated with better clinical outcomes. Altogether, clinical trials 
also support the concept that, though long-term cure is possible in a subset of 
patients, allogeneic HSCT has so far benefited a minority of younger patients with 
matched sibling donors.  
Acute and chronic GvHD (reviewed in Chapter 11 by Antin and Korngold 
and Chapter 12 by Martin and Pavletic, respectively) have been the most 
challenging transplant-related complication occurring up to 60% in T-replete 
allografts. The incidence of GvHD may further increase with patient age, with the 
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use of unrelated or mismatched donors and female donors, especially if 
multiparous (125).Though, GvHD has also been associated with decreased risk of 
disease relapse (110), no recent changes in its treatment have yet translated into 
significant survival advantages. Most early clinical trials on myeloablative 
allografting included bone marrow grafts. G-CSF mobilised PBSC have recently 
been increasingly utilized as a source of stem cells especially in patients with 
HLA-identical sibling donors. The biological differences of the graft composition 
may have an important clinical impact. In PBSC grafts, the content of T cells is 
significantly higher as well as their polarisation toward a Th-2 cell phenotype 
more typically observed during active chronic GvHD. The EBMT analysis 
reported a trend toward higher chronic GvHD in PBSC recipients; however, the 
short follow-up did not allow to draw conclusions on the ultimate impact on 
clinical outcome of the use of PBSC (122). Though no higher incidence and 
severity of acute GvHD have been reported, it is still controversial if the use of 
PBSC is correlated with a higher incidence of extensive GvHD that may affect 
quality of life and clinical outcomes (126-128). Currently, prospective 
randomised studies comparing bone marrow vs. PBSC grafts in hematological 
malignancies are in progress.     
Many laboratory parameters have been used to predict prognosis in 
myeloma patients undergoing allogeneic HSCT. Low albumin and high 2-
microglobulin have been associated with worse clinical outcome after allografting 
(110,122). Newer biological parameters have recently been more helpful to 
categorize patients. Chromosome 13 deletion [del(13)], detected by standard 
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cytogenetics or FISH, has been the genetic abnormality most commonly 
associated with worse prognosis in several studies (72,129,130). However, a 
recent more comprehensive analysis failed to define del(13) as an independent 
prognostic factor. In fact, its prognostic significance appeared to be associated 
with the presence of other abnormalities such as t(4;14) and del(17p) (131). In the 
near future, advanced technologies such as gene-expression profiling may allow 
to correlate the genetic constitution and the biological behavior of the disease and 
determine how these factors influence prognosis (85,86,132). However, these 
molecular technologies are not readily available at most Institutions and their 
translational role in clinical practice remains to be determined in future years.  
 
ALLOGRAFTING AFTER NON-MYELOABLATIVE/REDUCED INTENSITY 
CONDITIONING REGIMENS  
 
 The association of allografting with long-term disease-free survival in a 
subset of patients suggested that graft-versus-myeloma effects may have 
potentially been curative for myeloma. This observation led to the exploration of 
less intense, highly immunosuppressive, though less myelosuppressive, 
conditioning regimens, aimed at establishing stable donor engraftment while 
drastically reducing organ toxicity. One of the most widely used conditionings 
was developed by the Seattle group based upon pre-clinical studies on the dog 
model which showed that donor engraftment could be obtained after a non-
myeloablative regimen consisting of low dose of TBI of 200 cGy coupled with 
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potent post-transplant immunosuppression with cyclosporine and mycophenolic 
acid (mycophenolate mofetil) (133). This strategy was soon translated into 
clinical studies. However, in the first 18 myeloma patients treated with this 
approach, two rejections of the donor cells were observed, and only transient CCR 
and partial remission were achieved in two and three patients, respectively (134). 
These results indicated that it would be imperative to explore the effects of more 
effective cytoreduction before non-myeloablative allogeneic HSCT to improve 
responses. A new treatment modality, especially for newly diagnosed patients 
who had not been heavily pre-treated, involved an autologous HSCT followed, 2 
to 4 months later, by a TBI-based non-myeloablative allogeneic HSCT (109). As 
compared to myeloablative conditioning, designed to produce simultaneous 
cytoreduction and adequate immunosuppression to establish stable donor 
engraftment, the tandem autologous-allogeneic approach allows to separate in 
time the high-dose cytoreduction and the graft-versus-myeloma effect with the 
potential of reducing treatment-related toxicity. The first multi-center experience 
with this approach included 54 stage II-III patients, median age 52 years (range, 
27-71), half of them with refractory or relapsed myeloma (109). Fifty-two patients 
completed the tandem autologous-allogeneic HSCT procedure. CCR was reported 
in 57%, and overall TRM was 22%. Overall chronic GvHD developed in 60%. 
After a median follow-up of 60 months, overall and progression free survivals 
were 69% and 38% respectively.  
 Overall, in recent years, a number of reduce-intensity regimens (table 2) 
have been introduced into phase II clinical trials including intermediate-dose 
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melphalan (100-140 mg/m
2
), with or without fludarabine, 200 cGy TBI 200 alone 
or with fludarabine, and intermediate-dose busulfan (135-143).  
Anti-thymocyte globulin or the anti-CD52 antibody alemtuzumab have 
also been included in some studies to reduce GvHD (136,142). Even though there 
is no consensus on which regimen is superior in terms of toxicity and efficacy, a 
planned autologous HSCT followed by a non-myeloablative or reduced-intensity 
allogeneic HSCT with G-CSF mobilized PBSC to reduce the risk of graft 
rejection and, possibly, determine higher graft-versus-myeloma effects appears to 
be the most widely used approach (108,109).  
Recently, an EBMT study has retrospectively compared the clinical 
outcomes of allogeneic HSCT after either reduced-intensity or myeloablative 
conditioning regimens in patients transplanted between 1998-2002 (144). One-
hundred-ninety-six patients conditioned with myeloablative regimens were 
compared with 321 patients conditioned with non-myeloablative or reduced-
intensity regimens between 1998-2002. Though TRM was significantly lower in 
the reduced-intensity group (24% vs. 37% at 2 years, p = 0.002), no statistical 
differences in overall and progression-free survivals were observed between the 
two groups by multivariate analysis. This finding was due to significantly higher 
relapse rate in the reduced-intensity group (p = 0.0001). The use of less intense 
regimens can indeed come at the cost of higher relapse rates, however, the 
conclusions of this study should be considered with some caution as many 
selection biases are evident between the two cohorts of patients. In the reduced-
intensity group, there was a remarkably higher number of patients who failed one 
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or more autologous transplants, more patients with refractory disease, and more 
T-cell depleted allografts, and higher use of unrelated donors. 
The concept of “Mendelian or genetic randomization” has recently been 
applied to assess clinical outcomes between patients with hematological 
malignancies treated with allografting or other therapies (145-148).
 
Though not 
universally accepted, this method relies on the biological process, described by 
Mendel, through which offspring randomly inherit genetic traits half from the 
mother and half from the father. One in four siblings is then expected to have a 
potential HLA-identical sibling donor. The comparison by the intention-to-treat 
principle between patients with HLA-identical siblings, who can be assigned to 
allografting, and those without, who cannot receive an allograft, is used as a 
surrogate for an unbiased randomization. Only a formal statistical randomization, 
however, between patients with suitable donors could provide stronger evidence. 
A French study initially compared two protocols which enrolled high risk 
myeloma patients in the light of elevated serum β2-microglobulin and del(13) 
(149). All patients underwent a first autologous transplant after high dose 
melphalan at 200 mg/m
2
. Sixty-five patients with HLA-identical sibling donors 
received an allograft after a reduced intensity conditioning with busulfan, 
fludarabine and high-dose anti-thymocyte globulin at 12.5 mg/kg. These patients 
were compared with 219 patients without a suitable sibling donor who were 
treated with a second autograft after melphalan at 220 mg/m
2
. TRM and response 
rates were not statistically different. After a median follow-up of 2 years, overall 
and event free survivals were 35% and 25%, and 41% and 30% for the double 
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autologous and the autologous-allogeneic groups, respectively. These findings 
may indicate that patients with poor prognostic factors such as del(13) and high 
β2-microglobulin may not benefit from reduced-intensity allogeneic HSCT. 
Though a remarkably low 7% incidence of chronic GvHD was reported, the high 
dose of anti-thymocyte globulin is a matter of concern as it may have highly 
prevented a strong graft-vs.-myeloma effect. However, another report by Kroger 
et al. showed that del(13) was an independent, poor-risk factor for overall and 
progression-free survival after reduced-intensity allogeneic HSCT, given a higher 
risk of relapse (150). A recent study reported on 245 consecutive myeloma 
patients, up to the age of 65 years, who were newly diagnosed between 1998-
2004. One-hundred-sixty-two of 199 patients with at least one sibling were HLA-
typed with their potential sibling donors. All patients received induction with two 
to three cycles of VAD-based regimens, cyclophosphamide and G-CSF for PBSC 
mobilization followed by autologous HSCT after melphalan at 200 mg/m
2
 (151). 
Eighty patients with an HLA-identical sibling were offered TBI-based non-
myeloablative conditioning followed by allogeneic HSCT with G-CSF mobilized 
PBSC, whereas 82 patients without an HLA-identical sibling were assigned to 
receive a second autologous transplant after high-dose (140-200 mg/m
2
) or 
intermediate-dose (100 mg/m
2
) melphalan-based conditioning regimens. The new 
feature of this study was the assignment of treatment in function of a single 
criterion: presence/absence of an HLA-identical sibling donor, regardless of 
disease stage and prognostic factors. By intent-to-treat analysis, after a median 
follow up of 45 months, overall and event-free survivals were significantly longer 
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in patients with donors: 80 versus 54 months (p = 0.01) and 35 versus 29 months 
(p = 0.02), respectively. By multivariate analysis, the presence of HLA-identical 
siblings was an independent variable significantly associated with longer overall 
and event-free survivals. Fifty-eight and 46 patients completed the tandem 
autologous-allogeneic and the tandem autologous HSCT programs, respectively. 
CCR rates were 55% and 26% with the tandem autologous-allogeneic and the 
tandem autologous (p = 0.004), whereas TRM was 10% and 2% respectively (p = 
non-significant). Median overall survival was not reached in the tandem 
autologous-allogeneic group and was 58 months in the tandem autologous group 
(p = 0.03). Event-free survival was 43 and 33 months, respectively (p=0.07). 
Given that cytogenetic information was available in only a third of the patients 
registered in the study, the impact of del(13) after the tandem autologous-
allogeneic HSCT approach could not be determined. However, though 
exploratory with low statistical power, a stratified analysis on the intent-to-treat 
population that defined high risk patients in the light of high 2-microglobulin 
levels or del(13), reported adjusted hazard ratios of 0.34 and 0.52 for overall and 
event-free survivals, respectively, similar to those obtained in the whole series. 
This finding suggests that patients with an HLA-identical sibling have better 
overall and event-free survivals as compared to those without an HLA-identical 
sibling. Large prospective studies, based on the Mendelian randomization 
principle, such as the BMT-CTN-0102 trial in the U.S.A. and the Dutch-Belgian 
Hemato-Oncology Cooperative Group (H.O.V.O.N.) trial in Europe are currently 
in progress and will offer helpful information to determine the role of the tandem 
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autologous-allogeneic HSCT approach using a TBI-based non-myeloablative 
conditioning regimen in the next few years. An extended phase II trail of 106 
newly diagnosed myeloma patients transplanted with the Seattle regimen was 
recently presented by Italian Group for Bone Marrow Transplantation 
(G.I.T.M.O.) (152). After a median follow-up of 54 months, overall survival was 
not reached and event-free survival was 35 months. Overall response, defined as 
combined CCR and partial remission, was 91% with 53 patients achieving CCR 
after allografting. Response prior to allogeneic HSCT was significantly associated 
with the achievement of post-transplant CCR and longer event-free survival. 
Interestingly, chronic GvHD was not correlated with either the achievement of 
CCR or response duration.   
 
GRAFT-VERSUS-MYELOMA EFFECTS AND GRAFT-VERSUS-HOST 
DISEASE 
 
The unique and potentially eradicating effect of allografting relies on the 
immune attack of donor T cells against disease-specific antigens capable of 
inducing a potent graft-versus-myeloma effect. Initial evidence for the existence 
of such an effect was the transfer of myeloma idiotype-specific immunity from an 
actively immunised marrow donor to the recipient (153). Anecdotal observations 
of complete responses after the infusion of donor lymphocytes or withdrawal of 
immunosuppression in patients with persistent or relapsed disease after 
allografting were further evidence (154-157). Subsequent larger studies showed 
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that, though donor lymphocyte infusions (DLI) could induce response rates up to 
50%, durable complete responses were, however, achieved in only a minority of 
patients (103,158,159). Furthermore, this cell therapy was often associated with 
clinical GvHD. Lokhorst et al. reported on 27 relapsed patients who received 52 
DLI at a median of 30 months after allogeneic HSCT (160,161). Debulking 
therapy was administered to 13 patients before DLI. Overall 14 patients (52%) 
responded, including 6 (22%) who achieved CCR. Major toxicity was acute and 
chronic GvHD present in 55% and 26% of patients respectively. Median overall 
survival was 18 months, 11 for patients who did not respond and not yet reached 
for responding patients. Other studies reported that the strongest predictors for 
response following DLI were acute and chronic GvHD (162,163). The Authors 
concluded that both GvHD and graft-versus-myeloma shared the same antigenic 
targets.  
GvHD and its treatment-related complications have always been a matter 
of concern for clinicians. Moreover, chronic GvHD can highly affect the patient’s 
quality of life. GvHD can indeed be almost completed eliminated by T-cell 
depletion of the donor graft. However, this manipulation has invariably been 
associated with higher risk of relapse of the underlying hematological 
malignancies (164). Though the experience is limited in myeloma, partial T-cell 
depletion to allow donor engraftment and limit the risk of GvHD has also been 
investigated. Alyea et al. used a myeloablative conditioning regimen followed by 
a CD6-depleted donor bone marrow graft. Selected CD4
+
-donor lymphocytes 
were infused later to evoke graft-versus-myeloma effect (112). The incidence of 
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grade II-III GvHD was 21%, and TRM was 10%. Only one patient achieved a 
CCR at 6 months without the addition of donor lymphocytes. Fourteen out of 24 
patients received donor lymphocytes and response was observed in 10 pateints, 
with 7 developing acute or chronic GvHD. Two-year overall and progression-free 
survivals were 55% and 42% respectively. Importantly, donor lymphocytes could 
not be given as scheduled to 42% of patients, either as a result of GvHD or other 
transplant-related complications. The use of alemtuzumab (a.k.a. Campath), a 
monoclonal anti-CD52 antibody, has also been explored to reduce the incidence 
of GvHD, either by treatment "in the bag" or by systemic infusion prior to the 
conditioning regimen (136,165). Though the incidence of GvHD was significantly 
reduced, the use of alemtuzumab clearly affected disease responses and their 
duration (136). All these observations clearly indicate the important role of donor 
T cells in providing efficient graft-versus-myeloma activity. Lokhorst et al. 
recently reported on a prospective phase III study by the H.O.V.O.N. group 
(166,167). Fifty-three patients with an HLA-identical sibling underwent a 
partially T-cell-depleted allograft as part of their initial treatment plan. The 
overall response was 89%, including 19% CCR. After a median follow-up of 38 
months post-transplant, 20 patients were alive and 33 dead, 14 from progressive 
disease and 18 from TRM. Median overall and progression-free survivals after 
allografting were 17 and 25 months respectively. Only 3 patients were in 
continuous CCR. This prospective multi-center study did not support the use of T-
cell-depleted myeloablative allogeneic HSCT in myeloma. The strategy of pre-
emptive DLI after partially T-cell depleted allografting has also been evaluated. 
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Levenga et al. reported on 24 myeloma patients treated with a partially T-cell-
depleted myeloablative allogeneic HSCT (168). Patients enrolled in the study 
were intended to receive subsequent pre-emptive DLI. Twenty of 24 patients 
responded with 10 patients (42%) reaching complete remission. One-year TRM 
was 29%. Overall, 13 patients (54%) received pre-emptive lymphocyte infusions. 
GvHD higher than grade I following the infusion developed in 4 (30%). After a 
median follow-up of 67 months, 11 patients (46%) were alive, 7 of whom (29%) 
in continuous CCR including 4 in molecular remission. All these patients had 
received pre-emptive lymphocytes. 
Though GvHD was associated with disease response in the majority of 
clinical trials, it is encouraging that more recent studies employing non-
myeloablative conditionings did not correlate disease response and its duration 
with the development of chronic GvHD (151,152). In a recent evaluation of 106 
patients enrolled in a prospective phase II study, the development of both acute or 
chronic GvHD was not significantly associated with either the achievement of 
complete remission or its duration post transplant (152). This is consistent with 
the notion that GvHD may be not essential for graft-versus-myeloma, though the 
relationship between the two phenomena appeared strong in studies employing 
myeloablative conditioning. New methods to augment graft-versus-myeloma 
effects to allow long-term disease control and possibly decrease toxicity are 
presented below.  
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FUTURE DEVELOPMENTS 
 
Tandem autologous-allogeneic HSCT approaches are currently widely used in 
clinical trials. The rationale of the tandem approach is to separate temporally the 
high-dose chemotherapy from allografting, to combine the benefits of autologous 
HSCT (higher disease response and prolonged survival compared to conventional 
chemotherapy) and allogeneic HSCT (graft-versus-myeloma effects)
 
while 
reducing transplant-related toxicities. Drastic reduction in early TRM and CCR 
rates of over 50% including molecular remissions have been reported. However, 
the risk of relapse is not negligible. New methods to augment graft-versus-
myeloma effects should be explored to allow better long-term disease control. For 
this purpose, allogeneic HSCT and new drugs with molecular targets, such as 
thalidomide, lenalidomide and bortezomib, should not be viewed as mutually 
exclusive. Bortezomib and thalidomide re-induce responses in relapsed patients 
following allografting and may also be employed to achieve profound 
cytoreduction and reduce myeloma to a minimal residual state before allografts 
(169-172).
 
Thus, it is imperative to thoroughly explore their roles in increasing the 
efficacy of tandem autologous-allogeneic HSCT. Major improvements will also 
lye in the separation of the potentially eradicating graft-versus-myeloma effects 
from the detrimental GvHD. New insights into the pathophysiology of acute 
GvHD have led to the development of conditioning regimens with total-lymphoid 
irradiation that reduce its incidence, but appear to preserve the anti-tumor effects 
Chap 14 - 49 
of donor T cells (173). Furthermore, the identification of disease-specific antigens 
may trigger more potent myeloma-specific immune responses of donor cytotoxic 
T cells (174). The recurrent observation that allografting at an earlier phase of the 
disease is associated with more effective GVM may also be related to an 
expression profile of potential antigenic targets for T cells that varies through the 
various disease phases. Siegel et al. recently identified HLA-A*0201-presented T 
cell epitopes derived from the oncofetal antigen-immature laminin receptor 
protein in hematological cancers which include myeloma (175). However, the 
expression of these antigens on myeloma cells is lost when the disease is 
advanced. In conclusion, the therapeutic role of allogeneic HSCT will ultimately 
be determined in control studies where patients are allocated treatment in the light 
of prognostic factors and groups are confronted in a randomized fashion.
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Figure 1. In a subgroup of 253/351 patients FISH analysis for amplification of 1q21 was performed.  An inferior 
event-free survival was observed in patients with CA and amplification of 1q21 in the overall group and in ISS 
stages 1 and 2.  Patients with CCND1 spikes were grouped with those lacking CA or amplification of 1q21 or both.
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Figure 2: Overall Survival according to salvage therapy 
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Figure 3 depicts Kaplan-Meier plots of the durations of OS and EFS.  Univariate 
and multivariate regression analyses revealed that CR, EFS and OS durations 
were independently favorably affected by the absence of metaphase cytogenetic 
abnormalities (CA) of the deletion13/hypodiploidy variety (“CA13/hypo”), low 
B2-microglobulin and CRP levels, and higher albumin and platelet 
concentrations.
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Table 1. Myeloablative Conditioning Regimens Utilized for Allogeneic 
HSCT in Multiple Myleoma 
 
Author 
Patien
ts 
Median 
Age 
(years) 
Donor 
Related/Unrel
ated 
Conditioning 
Transplant-
Related 
Mortality, %  
Complete 
Remission, %  
Overall 
Survival, %  
Bensinger et 
al.
11,15 
136 
43-48 
(<60) 
114/22 Bu, Cy, +TBI 
48 (at day 100)  
63 (at 1 year) 
34 
22  (at 5 
years) 
Barlogie et 
al.
16 
36 <55 36/0 
Melphalan (100 mg/m
2
), TBI 
(12Gy) 
53 (at 1 year) --- 
39  (at 7 
years) 
Reece et al.
17 
26 43 22/4 
Cy,TBI  
Bu,Cy 
Melphalan (100 mg/m
2
), TBI 
19 (at day 100) 62 
47  (at 3 
years) 
Alyea et al.
18 
24 46 24/0 
Cy,TBI (14Gy) 
Bu,Cy 
10 --- 
55  (at 2 
years) 
Kulkarni et 
al.
19 
33 38 29/4 
Melphalan (110 mg/m
2
), TBI 
(10.5Gy) Cy, TBI (9.5Gy) 
Cy, Melphalan 
Bu,Cy 
54 37 36 (at 3 years) 
Le Blanc et 
al.
20 
37 47 37/0 
Cy, TBI (12Gy) 
Melphalan (140 mg/m
2
), TBI 
(10.5Gy)  
Bu,Cy 
Others 
22 57 
32 (at 40 
months) 
Couban et 
al.
21 
22 43 22/0 
Melphalan (160 mg/m
2
), TBI 
(12Gy)  
Cy, TBI (12Gy)  
Bu,Cy  
59 50 32 (at 3 years) 
Chap 14 - 81 
Varterasian 
et al.
22 
24 43 --- 
Cy, TBI 
Melphalan, TBI  
Bu,Cy, TMI 
Others 
25 --- 40 (at 3 years) 
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Table 1. Nonmyeloablative and Reduced Intensity Conditioning 
Regimens Utilized for Allogeneic HSCT in Multiple Myeloma 
 
Author 
Patien
ts 
Donor 
Related/Unrel
ated 
Conditioning 
Transplant-
Related 
Mortality, %  
Chronic 
GVHD, %  
Complete 
Remission, %  
Overall 
Survival, %  
Mohty et 
al.
44 
41 41/0 Bu, Fluda, ATG 17 41 24 
62  (at 2 
years) 
Peggs et 
al.
45 
20 12/8 
TBI, Fluda,  
alemtuzumab
1 
15 --- 10 
71  (at 2 
years) 
Einsele et 
al.
46 
22 7/15 TBI(2Gy), Fluda, Cy 23 32 27 
26  (at 2 
years) 
Giralt et 
al.
47 
22 11/9 
Fluda , Melphalan 
(90/140 mg/m
2
) 
41 27 32 
30  (at 2 
years) 
Gerull et 
al.
48 
52 32/20 TBI(2Gy), Fluda 17 70 27 
41 (at 1.5 
years) 
Bruno et 
al.
49 
22 0/22 TBI(2Gy), Fluda 18 61 20 
79 /27  (at 2 
year) 
Maloney et 
al.*
14 
54 52/0 
TBI(2Gy)/(2Gy)TBI, 
Fluda 
22 60 57 
69 (at 5 
years) 
Lee et al.
50 
45 33/12 
Melphalan (100 
mg/m
2
), TBI(2Gy), 
Fluda 
38 13 64 
36 (at 3 
years) 
Kroger et 
al.*
13 
17 9/8 
Melphalan (100 
mg/m
2
), Flu, ATG 
18 7 73 
74 (at 2 
years) 
Kroger et 
al.
51 
21 0/21 
Melphalan (100-140 
mg/m
2
), Flu, ATG 
24 12 40 
74 (at 2 
years) 
Galimberti 
et al.*
52 
20 20/0 
TBI(2Gy), Fluda /Cy, 
Fluda 
20 30 35 
58 (at 2 
years) 
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